These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36973704)

  • 1. HES1-mediated down-regulation of miR-138 sustains NOTCH1 activation and promotes proliferation and invasion in renal cell carcinoma.
    Liu S; Dou L; Miao M; Man X; Wei B; Jiang Z; Ouyang Y; Ozaki T; Yu M; Zhu Y
    J Exp Clin Cancer Res; 2023 Mar; 42(1):72. PubMed ID: 36973704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
    Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
    Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased miR-200a-3p is a key regulator of renal carcinoma growth and migration by directly targeting CBL.
    Ding M; Sun X; Zhong J; Zhang C; Tian Y; Ge J; Zhang CY; Zen K; Wang JJ; Zhang C; Wang C
    J Cell Biochem; 2018 Dec; 119(12):9974-9985. PubMed ID: 30171729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA HCG11/miR-579-3p/MDM2 axis modulates malignant biological properties in pancreatic carcinoma via Notch/Hes1 signaling pathway.
    Xu J; Xu W; Yang X; Liu Z; Sun Q
    Aging (Albany NY); 2021 Jun; 13(12):16471-16484. PubMed ID: 34230221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-532-5p suppresses renal cancer cell proliferation by disrupting the ETS1-mediated positive feedback loop with the KRAS-NAP1L1/P-ERK axis.
    Zhai W; Ma J; Zhu R; Xu C; Zhang J; Chen Y; Chen Z; Gong D; Zheng J; Chen C; Li S; Li B; Huang Y; Xue W; Zheng J
    Br J Cancer; 2018 Aug; 119(5):591-604. PubMed ID: 30082686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-6838-5p facilitates the proliferation and invasion of renal cell carcinoma cells through inhibiting the DMTF1/ARF-p53 axis.
    Zhai X; Wu Y; Zhang D; Li H; Chong T; Zhao J
    J Bioenerg Biomembr; 2021 Apr; 53(2):191-202. PubMed ID: 33686550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasis-related genes.
    Chen X; Ruan A; Wang X; Han W; Wang R; Lou N; Ruan H; Qiu B; Yang H; Zhang X
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1295-304. PubMed ID: 24802708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular Vesicles Carrying miR-887-3p Promote Breast Cancer Cell Drug Resistance by Targeting BTBD7 and Activating the Notch1/Hes1 Signaling Pathway.
    Wang B; Wang Y; Wang X; Gu J; Wu W; Wu H; Wang Q; Zhou D
    Dis Markers; 2022; 2022():5762686. PubMed ID: 35655918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirt3 promotes the autophagy of HK‑2 human proximal tubular epithelial cells via the inhibition of Notch‑1/Hes‑1 signaling.
    Wang Y; Chang J; Wang ZQ; Li Y
    Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circ_0000274 contributes to renal cell carcinoma progression by regulating miR-338-3p/NUCB2 axis and JAK1/STAT3 pathway.
    Qi Q; Sun Y; Yang Y; Liu Y
    Transpl Immunol; 2022 Oct; 74():101626. PubMed ID: 35569717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-28-5p acts as a tumor suppressor in renal cell carcinoma for multiple antitumor effects by targeting RAP1B.
    Wang C; Wu C; Yang Q; Ding M; Zhong J; Zhang CY; Ge J; Wang J; Zhang C
    Oncotarget; 2016 Nov; 7(45):73888-73902. PubMed ID: 27729617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-378a-3p promotes renal cell carcinoma proliferation, migration, and invasion by targeting TOB2.
    Bao N; Zhang P; Zhu Y; Du P; Jin G; Wu B; Ding T
    Clin Transl Oncol; 2023 Mar; 25(3):748-757. PubMed ID: 36309620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of microRNA-15a suppresses the proliferation and invasion of renal cell carcinoma via direct targeting of eIF4E.
    Li G; Chong T; Xiang X; Yang J; Li H
    Oncol Rep; 2017 Oct; 38(4):1995-2002. PubMed ID: 28849086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of microRNA-182-5p contributes to renal cell carcinoma proliferation via activating the AKT/FOXO3a signaling pathway.
    Xu X; Wu J; Li S; Hu Z; Xu X; Zhu Y; Liang Z; Wang X; Lin Y; Mao Y; Chen H; Luo J; Liu B; Zheng X; Xie L
    Mol Cancer; 2014 May; 13():109. PubMed ID: 24886554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Zhu H; Wang K; Yang L; Xu Q; Ren F; Liu X
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Dec; 40(12):1703-1711. PubMed ID: 33380402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-21-5p serves as a promoter in renal cell carcinoma progression through ARHGAP24 downregulation.
    Meng B; Wang P; Zhao C; Yin G; Meng X; Li L; Cai S; Yan C
    Environ Sci Pollut Res Int; 2022 Jun; 29(26):39985-39993. PubMed ID: 35112252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma.
    Li Y; Guan B; Liu J; Zhang Z; He S; Zhan Y; Su B; Han H; Zhang X; Wang B; Li X; Zhou L; Zhao W
    EBioMedicine; 2019 Jun; 44():439-451. PubMed ID: 31130475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notch1 pathway-mediated microRNA-151-5p promotes gastric cancer progression.
    Hsu KW; Fang WL; Huang KH; Huang TT; Lee HC; Hsieh RH; Chi CW; Yeh TS
    Oncotarget; 2016 Jun; 7(25):38036-38051. PubMed ID: 27191259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CircRNA SCARB1 Promotes Renal Cell Carcinoma Progression Via Mir- 510-5p/SDC3 Axis.
    Sun J; Pan S; Cui H; Li H
    Curr Cancer Drug Targets; 2020; 20(6):461-470. PubMed ID: 32271695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma.
    Cui L; Zhou H; Zhao H; Zhou Y; Xu R; Xu X; Zheng L; Xue Z; Xia W; Zhang B; Ding T; Cao Y; Tian Z; Shi Q; He X
    BMC Cancer; 2012 Nov; 12():546. PubMed ID: 23173671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.